GSK plc (LON:GSK - Get Free Report) insider Emma Walmsley purchased 9 shares of the business's stock in a transaction that occurred on Tuesday, September 9th. The stock was bought at an average cost of GBX 1,486 per share, for a total transaction of £133.74.
Emma Walmsley also recently made the following trade(s):
- On Monday, August 11th, Emma Walmsley bought 9 shares of GSK stock. The shares were acquired at an average cost of GBX 1,408 per share, for a total transaction of £126.72.
GSK Stock Performance
GSK stock traded down GBX 5.02 during mid-day trading on Wednesday, hitting GBX 1,485.98. 5,415,231 shares of the company's stock traded hands, compared to its average volume of 12,375,177. GSK plc has a one year low of GBX 1,242.50 and a one year high of GBX 1,675. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The firm has a 50 day moving average price of GBX 1,423.05 and a 200 day moving average price of GBX 1,431.86. The company has a market cap of £59.85 billion, a PE ratio of 1,796.83, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.
GSK (LON:GSK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported GBX 75.30 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, equities analysts forecast that GSK plc will post 175.980975 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on the company. JPMorgan Chase & Co. lowered their price target on GSK from GBX 1,460 to GBX 1,400 and set an "underweight" rating on the stock in a report on Monday, August 4th. Berenberg Bank reiterated a "hold" rating and issued a GBX 1,600 target price on shares of GSK in a research note on Friday, July 18th. Shore Capital restated a "buy" rating and set a GBX 2,100 price target on shares of GSK in a research note on Wednesday, August 27th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a GBX 1,450 price objective on shares of GSK in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of GBX 1,637.50.
Check Out Our Latest Report on GSK
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
